Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - corynebacterium pseudotuberculosis - unknown - corynebacterium pseudotuberculosis vaccine active 0.0 - active constituent

Estados Unidos - inglês - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13) - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) 25 [lf] in 0.5 ml - diphtheria and tetanus toxoids adsorbed is a vaccine indicated for active immunization against diphtheria and tetanus. diphtheria and tetanus toxoids adsorbed is approved for use in children from 6 weeks through 6 years of age (prior to 7th birthday). diphtheria and tetanus toxoids and acellular pertussis vaccine (dtap) or a dtap-containing vaccine is recommended for immunization of infants and children 6 weeks through 6 years of age. diphtheria and tetanus toxoids adsorbed should be used in instances where the pertussis vaccine component is contraindicated. diphtheria and tetanus toxoids adsorbed is not to be used for treatment of diphtheria or tetanus infection. a severe allergic reaction (e.g., anaphylaxis) after a previous dose of diphtheria and tetanus toxoids adsorbed or any other diphtheria toxoid or tetanus toxoid-containing vaccine, or any other component of this vaccine is a contraindication to administration of diphtheria and tetanus toxoids adsorbed. [see description (11). ] diphtheria and tetanu

Estados Unidos - inglês - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) 15 [lf] in 0.5 ml - daptacel® is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to seventh birthday). a severe allergic reaction (e.g., anaphylaxis) after a previous dose of daptacel or any other tetanus toxoid, diphtheria toxoid, or pertussis-containing vaccine, or any other component of this vaccine is a contraindication to administration of daptacel. [see description (11). ] because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered. encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, inclu

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - corynebacterium pseudotuberculosis toxoid & inactivated. - unknown - corynebacterium pseudotuberculosis toxoid & inactivated. vaccine-toxiod active 0.0 - active constituent

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - corynebacterium pseudotuberculosis (ovis) - toxoid - unknown - corynebacterium pseudotuberculosis (ovis) - toxoid vaccine-toxoid active 0.0 - active constituent

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

abbott rapid diagnostics pty ltd - ct913 - corynebacterium ivds - ivds intended to provide information on infection or exposure to corynebacterium bacteria or vaccines.

Estados Unidos - inglês - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) 15 [lf] in 0.5 ml - quadracel® is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis. a single dose of quadracel is approved for use as a fifth dose in the diphtheria, tetanus, pertussis (dtap) vaccination series, and as a fourth or fifth dose in the inactivated poliovirus (ipv) vaccination series in children 4 through 6 years of age whose previous dtap vaccine doses have been with pentacel® [diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine], daptacel® (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) and/or vaxelis (diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, haemophilus b conjugate and hepatitis b vaccine). severe allergic reaction (e.g., anaphylaxis) to any ingredient of quadracel [see description (11) ] or following any diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, or inactivated poliovi

Estados Unidos - inglês - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (unii: 8c367iy4ey) (bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) - unii:8c367iy4ey), bordetella pertussis pertactin antigen (formaldehyde inactivated) (unii: i05o535nv6) (bordetella pertussis pertactin antigen (formaldehyde inactivated) - unii:i05o535nv6), bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (unii: qsn5xo8zsu) (bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) - unii:qsn5xo8zsu), poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) 25 [iu] in 0.5 ml - a single dose of kinrix is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (dtap) vaccine series and the fourth dose in the inactivated poliovirus vaccine (ipv) series in children aged 4 through 6 years (prior to the seventh birthday) whose previous dtap vaccine doses have been with infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) and/or pediarix [diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis b (recombinant) and inactivated poliovirus vaccine] for the first 3 doses and infanrix for the fourth dose. severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid-, tetanus toxoid-, pertussis- or poliovirus-containing vaccine, or to any component of kinrix, including neomycin and polymyxin b, is a contraindication to administration of kinrix [see description (11)] . because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with any of these components should be given. alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is considered. encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine, including kinrix. progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy, is a contraindication to administration of any pertussis-containing vaccine, including kinrix. pertussis vaccine should not be administered to individuals with such conditions until a treatment regimen has been established and the condition has stabilized. safety and effectiveness of kinrix in children younger than 4 years and children aged 7 to 16 years have not been evaluated. kinrix is not approved for use in persons in these age groups.

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - hydroxocobalamin acetate; selenium as sodium selenate; corynebacterium pseudotuberculosis; clostridium perfringens type d toxoid; clostridium tetani - toxoid; thiomersal; aluminium (adjuvant) - parenteral liquid/solution/suspension - hydroxocobalamin acetate vitamin-b12 active 2.0 mg/ml; selenium as sodium selenate mineral-selenium active 1.0 mg/ml; corynebacterium pseudotuberculosis vaccine active 1.0 iu/ml; clostridium perfringens type d toxoid vaccine-toxoid active 5.0 iu/ml; clostridium tetani - toxoid vaccine-toxoid active 2.5 iu/ml; thiomersal mercury other 0.13 mg/ml; aluminium (adjuvant) mineral-aluminium other 0.0 p - immunotherapy - lamb | ovine - cheesy gland | cobalt deficiency | enterotoxaemia (pulpy kidney) | selenium responsive condition | tetanus | unthriftiness | vaccines and antisera | vitamin b12 deficiency | white muscle disease | anaemia | brown snake bite | cheesy gland | clostridium perfringens type d | cobalt deficiency | correct selenium responsive co | enterotoxaemia | ill - thrift | lymphadenitis | lymphangitis | prevent selenium responsive co | selenium deficiency | selenium responsive ill-thrift | stiff lamb disease | subacute enzootic muscular dys | tetanus | tetanus vaccination

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - clostridium perfringens type d toxoid; clostridium tetani - toxoid; corynebacterium pseudotuberculosis (ovis) - toxoid; thiomersal - misc. vaccines or anti sera - clostridium perfringens type d toxoid vaccine-toxoid active 0.0 u; clostridium tetani - toxoid vaccine-toxoid active 0.0 u; corynebacterium pseudotuberculosis (ovis) - toxoid vaccine-toxoid active 0.0 u; thiomersal mercury other 0.1 mg/ml - immunotherapy - goat | goat kid | lamb | sheep | billy | buck | capra hircus | doe | ewe | hogget | kid | lamb | ovine | ram | weaner | wether | - caseous lymphadenitis (cheesy gland) | enterotoxaemia (pulpy kidney) | tetanus | clostridium perfringens type d | tetanus vaccination